FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting
09 déc. 2023 17h02 HE
|
FibroGen, Inc.
please call Meichiel Keenan@650-219-6482 with any questions.
FibroGen Reports Third Quarter 2023 Financial Results
06 nov. 2023 16h01 HE
|
FibroGen, Inc.
Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in...
FibroGen to Report Third Quarter 2023 Financial Results
23 oct. 2023 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will also...
FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy
29 août 2023 16h15 HE
|
FibroGen, Inc.
– Study did not meet the primary endpoint – – Pamrevlumab was generally safe and well tolerated – SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced...
FibroGen Reports Second Quarter 2023 Financial Results
07 août 2023 16h01 HE
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
FibroGen Announces Leadership Transition
25 juil. 2023 07h00 HE
|
FibroGen, Inc.
Appoints Thane Wettig as Interim Chief Executive Officer Wettig succeeds Enrique Conterno and brings over 30 years of global pharmaceutical leadership SAN FRANCISCO, July 25, 2023 (GLOBE NEWSWIRE)...
FibroGen to Report Second Quarter 2023 Financial Results
24 juil. 2023 07h00 HE
|
FibroGen, Inc.
SAN FRANCISCO, July 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2023 financial results on Monday, August 7 after the market close. FibroGen will also...
FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis
26 juin 2023 07h04 HE
|
FibroGen, Inc.
- Study did not meet the primary endpoint- Pamrevlumab was generally safe and well tolerated- ZEPHYRUS-2 Phase 3 study will be discontinued- Company to implement plan to extend cash runway into...
FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy
07 juin 2023 06h55 HE
|
FibroGen, Inc.
Study did not meet the primary endpointPamrevlumab was generally safe and well tolerated Topline results from LELANTOS-2 Phase 3 study of pamrevlumab in ambulatory patients with DMD expected 3Q 2023 ...
FibroGen to Present at Jefferies Global Healthcare Conference
06 juin 2023 16h01 HE
|
FibroGen, Inc.
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following...